Rhenman & Partners Asset Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-370,000	Closed	-$2.01M	–	96
2022 Q4	$2.01M	Hold	370,000	–	–	0.21%	82
2022 Q3	$3.94M	Buy	370,000 +53,863	+17%	+$615K	0.41%	66
2022 Q2	$1.56M	Hold	316,137	–	–	0.18%	82
2022 Q1	$2.4M	Sell	316,137 -8,863	-3%	-$84K	0.24%	85
2021 Q4	$3.4M	Hold	325,000	–	–	0.23%	82
2021 Q3	$4.36M	Hold	325,000	–	–	0.31%	80
2021 Q2	$7.13M	Hold	325,000	–	–	0.48%	68
2021 Q1	$7.82M	Buy	325,000 +85,000	+35%	+$1.98M	0.55%	55
2020 Q4	$4.32M	Buy	240,000 +50,000	+26%	+$747K	0.35%	68
2020 Q3	$2.19M	Hold	190,000	–	–	0.2%	75
2020 Q2	$4.61M	Sell	190,000 -60,172	-24%	-$995K	0.5%	65
2020 Q1	$2.76M	Sell	250,172 -13,228	-5%	-$247K	0.39%	68
2019 Q4	$6.96M	Sell	263,400 -272,257	-51%	-$6.37M	0.76%	55
2019 Q3	$12.2M	Buy	535,657 +261,383	+95%	+$8.24M	1.53%	26
2019 Q2	$8.41M	Buy	274,274 +62,105	+29%	+$1.31M	0.93%	47
2019 Q1	$3.52M	Buy	212,169 +39,349	+23%	+$746K	0.41%	63
2018 Q4	$3.31M	Buy	+172,820	New	+$6.47M	0.38%	65

Other funds holding GTHX

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Rhenman & Partners Asset Management's GTHX Position: Q1 2023 in Review

Rhenman & Partners Asset Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q1 2023, closing a stake of 370,000 shares — an estimated $2.01M sold.

Rhenman & Partners Asset Management first reported a position in GTHX in Q4 2018 and held it in 17 quarters. The position peaked at $12.2M in Q3 2019. 96 funds tracked by Wall St. Rank hold GTHX as of Q1 2023.

Rhenman & Partners Asset Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Rhenman & Partners Asset Management sold 370,000 G1 Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $2.01M.
Rhenman & Partners Asset Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2018 and held it in 17 quarters.
Rhenman & Partners Asset Management's G1 Therapeutics, Inc. Common Stock position peaked at $12.2M in Q3 2019.
96 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2023, filed 12 May 2023.